Last updated: August 17, 2025
Introduction
European Patent EP2363391, titled "Method for Treatment of Tumors," was granted by the European Patent Office (EPO). It pertains to innovative methods for treating tumors, focusing on specific compounds and their application in oncology. This analysis delves into the patent's scope, claims, innovation landscape, and potential implications for stakeholders in pharmaceutical and biotech sectors.
Patent Overview and Summary
EP2363391 discloses methods involving the use of novel compounds or combinations thereof to enhance tumor treatment efficacy. The patent emphasizes targeted therapy, possibly involving kinase inhibitors or immune modulating agents, as indicated by the context of similar patent filings. Its core innovation lies in specific combinations, dosages, or delivery mechanisms designed to improve patient outcomes.
The patent, filed initially in 2009 and granted in 2014, encompasses multiple claims across several categories, including composition claims and method claims, with dependent claims expanding on specific embodiments.
Scope of the Patent
1. Technical Field
The patent resides primarily in oncology, particularly in the development of therapeutic interventions targeting tumors. The scope likely includes:
- Use of specific chemical agents for tumor treatment.
- Methods enhancing the efficacy of existing therapies.
- Combinations of agents with synergistic effects against cancer cells.
2. Geographical Coverage
While granted by the EPO, the patent's scope extends across multiple jurisdictions through its European coverage. It covers key European markets such as Germany, France, the UK, and potentially others via national phase entries.
Claims Analysis
3. Types of Claims
EP2363391 contains a structured hierarchy of claims:
- Independent Claims: Define the broadest scope of the invention.
- Dependent Claims: Narrow down the scope with specific embodiments, such as particular compounds, dosing regimens, or delivery routes.
4. Key Claim Elements
- Chemical Entities: The patent claims specific novel compounds, which may include kinase inhibitors or immune modulating agents.
- Methodology: Claims cover methods of administering the compounds, possibly involving combination therapies, specific schedules, or formulations.
- Therapeutic Application: The subject of the claims includes treatment of various tumor types, potentially including solid tumors and hematologic malignancies.
5. Claim Scope and Limitations
The independent claims are broad, aiming at protecting the general use of the compounds for tumor therapy. However, they are likely limited by:
- Specific structural features of the claimed compounds.
- Defined methods of administration.
- Particular tumor types or patient populations.
This structure balances broad protection with specificity to withstand patent challenges.
6. Potential Patentability and Validity
The claims' strength depends on prior art landscape, particularly existing kinase inhibitors or immune modulators; however, the novel combinations or specific claims of dosage and methods bolster their patentability. The scope's breadth invites scrutiny but remains defensible if the inventive step is properly demonstrated.
Patent Landscape and Competitive Environment
7. Related Patents and Overlap
The patent landscape surrounding EP2363391 includes numerous filings related to:
- Kinase inhibitors (e.g., EGFR, ALK inhibitors).
- Immune checkpoint modulators (e.g., PD-1, CTLA-4).
- Combination therapies in oncology.
Competitors such as AstraZeneca, Novartis, and Pfizer have active patent families targeting similar mechanisms, creating a competitive landscape that influences strategic patent filings and licensing.
8. Innovation and Differentiation
EP2363391's differentiation lies in its specific combination therapy approach, possibly including proprietary compounds or innovative administration regimens. Its claims likely carve out a niche by claiming novel chemical entities or methods not previously disclosed.
9. Patent Landscape Trends
- An increasing focus on combination therapies to overcome resistance.
- Expanding claims on personalized medicine approaches.
- Growing claims related to immune-oncology agents.
EP2363391 fits within these trends by targeting combination methods for tumor treatment.
Implications for Industry Stakeholders
10. For Patent Holders and Developers
- The broad independent claims provide extensive protection but require vigilant monitoring for potential infringement or challenge.
- Specific dependent claims can serve as fallback positions in litigation or licensing negotiations.
11. For Innovators and Researchers
- The patent underscores areas of active innovation, such as combination therapies targeting tumors.
- It highlights the importance of claiming specific compound structures and method steps to secure competitive advantage.
12. Regulatory and Commercial Considerations
- Patent protection facilitates investment in clinical development.
- The scope influences freedom-to-operate and market exclusivity in European territories.
Conclusion
EP2363391 exemplifies strategic patenting in oncology, securing protection over novel combination therapies targeting tumors. Its broad claims, supported by specific embodiments, provide a strong foothold in the competitive landscape of cancer therapeutics. Its validity depends on overcoming prior art, but the patent's focus on innovative methods and compositions contributes significantly to the patent landscape’s development. Stakeholders must navigate this complex environment carefully, leveraging the patent's scope for strategic advantage.
Key Takeaways
- EP2363391 covers broad methods employing specific compounds for tumor treatment, emphasizing combination therapy approaches.
- Its claims are carefully crafted to balance broad patentability with specificity, protecting core innovations while avoiding prior art.
- The patent landscape reflects a highly competitive environment focused on targeted and immune-oncology therapies.
- Strategic use of dependent claims enhances robustness, while vigilant monitoring is essential for enforcement.
- The patent's scope provides a valuable asset for licensing, partnership, and market exclusivity in Europe.
FAQs
1. What is the main innovation claimed in EP2363391?
It claims novel methods and compositions involving specific compounds and combination therapies for treating various tumor types, emphasizing improved efficacy or targeting mechanisms.
2. How does EP2363391 compare to other oncology patents?
Compared to existing patents, it emphasizes particular chemical entities and combination approaches, positioning itself within current innovation trends in immune and targeted therapies.
3. Can the claims of EP2363391 be challenged?
Yes, patentability can be challenged based on prior art, obviousness, or inventive step. The strength of claims depends on how well they distinguish from existing disclosures.
4. What is the potential for licensing based on this patent?
Given its broad scope in a high-value market, licensing opportunities are significant, especially for companies developing complementary or synergistic therapies.
5. How does the patent landscape influence future innovation?
It encourages detailed disclosures and claimed innovations, shaping research directions, and fostering strategic patent filings within the oncology sector.
Sources:
- European Patent Register: EP2363391.
- Espacenet Patent Database.
- Patent landscape reports on oncology therapeutics.
